Sputum interleukin‐6 level as a marker of severity during acute chest syndrome in children with sickle cell disease-Reference-Cited by-同舟云学术

Sputum interleukin‐6 level as a marker of severity during acute chest syndrome in children with sickle cell disease

Published:2024-05-23 Issue:1 Volume:205 Page:329-334
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Mayrand Lara¹²,Elie Juliette¹²,Pinhas Yael²³,Rignault‐Bricard Rachel¹³,Taylor Melissa²³,Brice Joséphine²³,de Montalembert Mariane²³,Heilbronner Claire⁴^ORCID,Beranger Agathe⁴⁵,Angyalosy Sofia⁴,Chhun Stephanie⁶,Maciel Thiago Trovati¹³,Hermine Olivier¹³⁷⁸,Allali Slimane¹²³^ORCID

Affiliation:

1. Laboratory of Cellular and Molecular Mechanisms of Hematological Disorders and Therapeutical Implications, Imagine Institute, Inserm U1163 Université Paris Cité Paris France

2. Department of General Pediatrics and Pediatric Infectious Diseases, Sickle Cell Center, Necker‐Enfants Malades Hospital, Assistance Publique – Hôpitaux de Paris (AP‐HP) Université Paris Cité Paris France

3. Laboratory of Excellence GR‐Ex Paris France

4. Department of Pediatric Intensive Care, Necker‐Enfants Malades Hospital, AP‐HP Université Paris Cité Paris France

5. URP7323 Pharmacologie et évaluation des thérapeutiques chez l'enfant et la femme enceinte Université Paris Cité Paris France

6. Laboratory of Immunology, Necker‐Enfants Malades Hospital, AP‐HP, INEM Institute, Inserm U1151 Université Paris Cité Paris France

7. Department of Hematology, Necker‐Enfants Malades Hospital, AP‐HP Université Paris Cité Paris France

8. Reference Center for Mastocytosis, Necker‐Enfants Malades Hospital, AP‐HP Paris France

Abstract

SummaryAcute chest syndrome (ACS) is a leading cause of morbimortality in sickle cell disease (SCD). In this prospective observational study, we investigated sputum interleukin‐6 (IL‐6) level as an ACS severity marker during 30 ACS episodes in 26 SCD children. Sputum IL‐6 levels measured within the first 72 h of hospitalisation for ACS were significantly higher in patients with oxygen requirement ≥2 L/min, ventilation (invasive and/or non‐invasive) length ≥5 days, bilateral and/or extensive opacities on chest X‐ray or erythrocytapheresis requirement. Sputum IL‐6 could serve as an ACS severity marker to help identify patients requiring targeted anti‐inflammatory treatments such as tocilizumab.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.19561

Reference16 articles.

1. Outcome of children with sickle cell disease admitted to intensive care - a single institution experience

2. Outcomes of Adult Patients With Sickle Cell Disease Admitted to the ICU

3. Causes and Outcomes of the Acute Chest Syndrome in Sickle Cell Disease

4. Acute Chest Syndrome in Children with Sickle Cell Disease

5. IL-6 levels are dramatically high in the sputum from children with sickle cell disease during acute chest syndrome